Seeking beyond rejection: An update on the differential diagnosis and a practical approach to liver allograft biopsy interpretation

Advances in Anatomic Pathology

Volumn 16, Issue 2, 2009, Pages 97-117

  Gao, Zu Hua ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Differential diagnosis; Liver; Pathology; Transplantation

Indexed keywords

BIOLOGICAL MARKER; HLA ANTIGEN; LYMPHOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ALLOTRANSPLANTATION; ANGIOGRAPHY; AUTOIMMUNE HEPATITIS; BILE DUCT INJURY; BILE DUCT OBSTRUCTION; BIOPSY; BLOOD GROUP ABO INCOMPATIBILITY; CHOLANGIOGRAPHY; CHRONIC GRAFT REJECTION; CHRONIC HEPATITIS; CLINICAL PRACTICE; DIFFERENTIAL DIAGNOSIS; DOPPLER FLOWMETRY; FIBROSIS; GOLD STANDARD; HEPATITIS B; HEPATITIS C; HISTOLOGY; HISTOPATHOLOGY; HLA SYSTEM; HUMAN; HUMORAL IMMUNITY; IMAGING AND DISPLAY; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER GRAFT; LIVER GRAFT REJECTION; LYMPHOPROLIFERATIVE DISEASE; NECROSIS; PATHOLOGIST; PATHOPHYSIOLOGY; PORTAL VEIN THROMBOSIS; PRACTICE GUIDELINE; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK FACTOR; SEPSIS; SEROLOGY;

BIOPSY; CYTOMEGALOVIRUS; DIAGNOSIS, DIFFERENTIAL; GRAFT REJECTION; HEPACIVIRUS; HUMANS; LIVER; LIVER TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 68649128111     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e31819946aa     Document Type: Review

References (186)

1. Anonymous. Terminology for hepatic allograft rejection. International working party. Hepatology. 1995;22:648-654.
2. Demetris AJ, Jaffe R, Tzakis A, et al. Antibody-mediated rejection of human orthotopic liver allografts. A study of liver transplantation across ABO blood group barriers. Am J Pathol. 1988;132:489-502. (Pubitemid 18224200)
3. Gugenheim J, Samuel D, Reynes M, et al. Liver transplantation across ABO blood group barriers. Lancet. 1990;336:519-523. (Pubitemid 20278096)
4. Manez R, Kelly RH, Kobayashi M, et al. Immunoglobulin G lymphocytotoxic antibodies in clinical liver transplantation: studies toward further defining their significance. Hepatology. 1995;21:1345-1352.
5. Takaya S, Bronsther O, Iwaki Y, et al. The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. Transplantation. 1992;53:400-406.
6. Furuya T, Murase N, Nakamura K, et al. Preformed lymphocytotoxic antibodies: the effects of class, titer and specificity on liver versus heart allografts. Hepatology. 1992;16:1415-1422.
7. Nakamura K, Murase N, Becich MJ, et al. Liver allograft rejection in sensitized recipients. Observations in a clinically relevant small animal model. Am J Pathol. 1993;142:1383-1391. (Pubitemid 24058125)
8. Sanchez-Urdazpal L, Sterioff S, Janes C, et al. Increased bile duct complications in ABO incompatible liver transplant recipients. Transplant Proc. 1991;23:1440-1441.
9. Haga H, Egawa H, Fujimoto Y, et al. Acute humoral rejection and C4d immunostaining in ABO blood type-incompatible liver transplantation. Liver Transpl. 2006;12:457-464.
10. Bellamy CO, Herriot MM, Harrison DJ, et al. C4d immunopositivity is uncommon in ABO-compatible liver allografts, but correlates partially with lymphocytotoxic antibody status. Histopathology. 2007;50:739-749.
11. Ploeg RJ, D'Alessandro AM, Knechtle SJ, et al. Risk factors for primary dysfunction after liver transplantation: a multivariate analysis. Transplantation. 1993;55:807-813. (Pubitemid 23122053)
12. Furukawa H, Todo S, Imventarza O, et al. Effect of cold ischemia time on the early outcome of human hepatic allografts preserved with UW solution. Transplantation. 1991;51:1000-1004.
13. Oh C-K, Sawyer RG, Pelletier SJ, et al. Independent predictors for primary non-function after liver transplantation. Yonsei Med J. 2004;45:1155-1161. (Pubitemid 40136677)
14. Imber CJ, St Peter SD, Handa A, et al. Hepatic steatosis and its relationship to transplantation. Liver Transpl. 2002;8:415-423. (Pubitemid 34520769)
15. Colina F, Lopez-Carreira M, Moreno E, et al. A clinicopathologic review of 8 liver graft primary nonfunctions. Hepatogastroenterology. 1995;42:212-221.
16. Wong J, Zhang Y, Lee SS. Hemodynamic characterization of arterialized and nonarterialized liver transplants in the rat. Can J Gastroenterol. 2001;15:435-440. (Pubitemid 32755672)
17. Stange BJ, Glanemann M, Nuessler NC, et al. Hepatic artery thrombosis after adult liver transplantation. Liver Transpl. 2003;9:612-620. (Pubitemid 36701699)
18. Gunsar F, Rolando N, Pastacaldi S, et al. Late hepatic artery thrombosis after orthotopic liver transplantation. Liver Transpl. 2003;9:605-611. (Pubitemid 36701698)
19. Oh CK, Pelletier SJ, Sawyer RG, et al. Uni- and multi-variate analysis of risk factors for early and late hepatic artery thrombosis after liver transplantation. Transplantation. 2001;71:767-772. (Pubitemid 32373692)
20. Dodd GD 3rd, Memel D, Zajko A, et al. Hepatic artery stenosis and thrombosis in transplant recipients: Doppler diagnosis with resistive index and systolic acceleration time. Radiology. 1994;192:657-661.
21. Pawlak J, Grodzki M, Leowska E, et al. Vascular complications after liver transplantation. Transplant Proc. 2003;35:2313-2315.
22. Orons PD, Sheng R, Zajko AB. Hepatic artery stenosis in liver transplant recipients: prevalence and cholangiographic appearance of associated biliary complications. Am J Roentgenol. 1995;165:1145-1149.
23. Abbasoglu O, Levy MF, Vodapally MS, et al. Hepatic artery stenosis after liver transplantation-incidence, presentation, treatment, and long term outcome. Transplantation. 1997;63:250-255. (Pubitemid 27121207)
24. Mondragon RS, Karani JB, Heaton ND, et al. The use of percutaneous transluminal angioplasty in hepatic artery stenosis after transplantation. Transplantation. 1994;57:228-231. (Pubitemid 24048590)
25. Raby N, Karani J, Thomas S, et al. Stenosis of vascular anastomosis after hepatic transplantation: treatment with balloon angioplasty. Am J Roentgenol. 1991;157:167-171.
26. Stange B, Settmacher U, Glanemann M, et al. Aneurysms of the hepatic artery after liver transplantation. Transplant Proc. 2000;32:533-534. (Pubitemid 30254389)
27. Nusseler N, Settmacher U, Haase R, et al. Diagnosis and treatment of arterial steal syndromes in liver transplant recipients. Liver Transpl. 2003;9:596-602. (Pubitemid 36701696)
28. Richter S, Mücker I, Menger MD, et al. Impact of intrinsic blood flow regulation in cirrhosis: maintenance of hepatic arterial buffer response. Am J Physiol Gastrointest Liver Physiol. 2000;279:G454-G462. (Pubitemid 30672753)
29. Geissler L, Lamesch P, Witzigmann H, et al. Splenohepatic arterial steal syndrome in liver transplantation: clinical features and management. Transpl Int. 2002;15:139-141. (Pubitemid 36061795)
30. Quintini C, Hirose K, Hashimoto K, et al. "Splenic artery steal syndrome" is a misnomer: the cause is portal hyperperfusion, not arterial siphon. Liver Transpl. 2008;14:374-379.
31. Sanchez-Urdazpal I, Gores GJ, Ward EM, et al. Diagnostic features and clinical outcome of ischemic-type biliary complications after liver transplantation. Hepatology. 1993;17:605-609. (Pubitemid 23115505)
32. Burton JR Jr, Rosen HR. Diagnosis and management of allograft failure. Clin Liver Dis. 2006;10:407-435.
33. Settmacher U, Nüssler NC, Glanemann M, et al. Venous complications after orthotopic liver transplantation. Clin Transplant. 2000;14:235-241. (Pubitemid 30242959)
34. Wang JT, Zhao HY, Liu YL. Portal vein thrombosis. Hepatobiliary Pancreat Dis Int. 2005;4:515-518.
35. Srinivasan P, Rela M, Prachalias A, et al. Liver transplantation for Budd-Chiari syndrome. Transplantation. 2002;73:973-977.
36. Melear JM, Goldstein RM, Levy MF, et al. Hematologic aspects of liver transplantation for Budd-Chiari syndrome with special reference to myeloproliferative disorders. Transplantation. 2002;74:1090-1095.
37. Cruz E, Ascher NL, Robers JP, et al. High incidence of recurrence and hematologic events following liver transplantation for Budd-Chiari syndrome. Clin Transplant. 2005;19:501-506. (Pubitemid 40990660)
38. Marcos A, Orloff M, Mieles L, et al. Functional venous anatomy for right-lobe grafting and techniques to optimize outflow. Liver Transpl. 2001;7:845-852. (Pubitemid 33040457)
39. Marcos A, Olzinski AT, Ham JM, et al. The interrelationship between portal and arterial blood flow after adult-to-adult living donor liver transplantation. Transplantation. 2000;70:1697-1703. (Pubitemid 32064822)
40. Lo CM, Fan ST, Chan JK, et al. Minimum graft volume for successful adult-to-adult living donor liver transplantation for fulminant hepatic failure. Transplantation. 1996;62:696-698.
41. Garcia-Valdecasas JC, Fuster J, Charco R, et al. Changes in portal vein flow after adult living-donor liver transplantation: does it influence postoperative liver function? Liver Transpl. 2003;9:564-569.
42. Tucker ON, Heaton N. The "small for size" liver syndrome. Curr Opin Crit Care. 2005;11:150-155.
43. Heaton N. Small-for-size liver syndrome after auxiliary and split liver transplantation: donor selection. Liver Transpl. 2003;9:S26-S28. (Pubitemid 37098862)
44. Demetris AJ, Kelly DM, Eghtesad B, et al. Pathophysiologic observations and histopathologic recognition of the portal hyperperfusion or small-for size syndrome. Am J Surg Pathol. 2006;30:986-993. (Pubitemid 44264948)
45. Garcia S, Roque J, Ruza F, et al. Infection and associated risk factors in the immediate postoperative period of pediatric liver transplantation: a study of 176 transplants. Clin Transplant. 1998;12:190-197. (Pubitemid 28269240)
46. Geier A, Fickert P, Trauner M. Mechanisms of disease: mechanisms and clinical implications of cholestasis in sepsis. Nat Clin Prac Gastroenterol Hepatol. 2006;3:574-585. (Pubitemid 44489590)
47. Lefkowitz JH. Bile ductular cholestasis: an ominous histopathologic sign related to sepsis and "cholangitis lenta". Hum Pathol. 1982;13:19-24.
48. Tachopoulou OA, Vogt DR, Henderson JM, et al. Hepatic abscess after liver transplantation: 1990-2000. Transplantation. 2003;75:79-83.
49. Mirza DF, Gunson GB, Soonawalla Z, et al. Reduced acute rejection after liver transplantation with Neoral-based triple immunosuppression. Lancet. 1997;349:701-702. (Pubitemid 27107756)
50. Höckerstedt K, Lautenschlager I, Ahonen J, Eklund B, Isoniemi H, Korsback C, et al. Diagnosis of acute rejection in liver transplantation. J Hepatol. 1988;6:217-221. (Pubitemid 18103547)
51. Wiesner RH, Demetris AJ, Belle SH, et al. Acute hepatic allograft rejection: incidence, risk factors and impact on outcome. Hepatology. 1998;28:638-645. (Pubitemid 28405409)
52. Seiler CA, Renner EL, Czerniak A, et al. Early acute cellular rejection: no effect on late hepatic allograft function in man. Transpl Int. 1999;12:195-201.
53. Krasinskas AM, Demetris AJ, Poterucha JJ, et al. The prevalence and natural history of untreated isolated central perivenulitis in adult's allograft livers. Liver Transpl. 2008;14:625-632.
54. Hübscher SG. Central perivenulitis: a common and potentially important finding in late posttransplant liver biopsies. Liver Transpl. 2008;14:596-600.
55. Rosen HR, Burton JR. Acute rejection in HCV-infected liver transplant recipients: the great conundrum. Liver Transpl. 2006;12:S38-S47. (Pubitemid 44742524)
56. Tannapfel A, Wittekind C. Differential diagnosis of acute rejection versus hepatitis reinfection. Transplant Proc. 2003;35:2082-2083. (Pubitemid 37194323)
57. Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology. 1998;28:823-830. (Pubitemid 28405436)
58. Demetris AJ, Eghtesad B, Marcos A, et al. Recurrent hepatitis C in liver allografts: prospective assessment of diagnostic accuracy, identification of pitfalls and observations about pathogenesis. Am J Surg Pathol. 2004;28:658-669. (Pubitemid 38579570)
59. Berenguer M, Crippin J, Gish R, et al. A model to predict severe HCV-related disease following liver transplantation. Hepatology. 2003;38:34-41. (Pubitemid 36775793)
60. Fiel MI, Agarwal K, Stanca C, et al. Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. Liver Transpl. 2008;14:861-871. (Pubitemid 351895516)
61. Demetris AJ, Sebagh M. Plasma cell hepatitis in liver allografts: variant of rejection or autoimmune hepatitis? Liver Transpl. 2008;14:750-755.
62. Anand A, Hubscher S, Gunson B, et al. Timing, significance and prognosis of late acute allograft rejection. Transplantation. 1995;60:1098-1103.
63. Andreu H, Rimola A, Bruguera M, et al. Acute cellular rejection in liver transplant recipients under cyclosporine immunosuppression: predictive factors of response to antirejection therapy. Transplantation. 2002;74:1936-1943. (Pubitemid 34701004)
64. Anonymous. Banff Schema for Grading Acute Liver Allograft Rejection: an international consensus document. Hepatology. 1997;25:658-663.
65. Demetris AJ, Ruppert K, Dvorchik I, et al. Real-time monitoring of acute liver allograft rejection using Banff schema. Transplantation. 2002;74:1290-1296. (Pubitemid 35402600)
66. Demirhan B, Bilexkçi B, Haberal AN, et al. Hepatic parenchyma changes and histologic eosinophilia as predictors of subsequent acute liver allograft rejection. Liver Transpl. 2008;14:214-219. (Pubitemid 351267279)
67. Anonymous. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology. 2006;44:489-501.
68. Pappo O, Ramos H, Starzl TE, et al. Structural integrity and identification of causes of liver allograft dysfunction occurring more than 5 years after transplantation. Am J Surg Pathol. 1995;19:192-206.
69. Tsamandas AC, Jain AB, Felekouras ES, et al. Central venulitis in the allograft liver: a clinicopathologic study. Transplantation. 1997;64:252-257. (Pubitemid 27332668)
70. Krasinskas AM, Ruchelli ED, Rand EB, et al. Central venulitis in pediatric liver allografts. Hepatology. 2001;33:1141-1147.
71. Angus PW, McCaughan GW, Gane EJ, et al. Combination low-dose hepatitis B immune globulin and lamivudine provided effective prophylaxis against post-transplantation hepatitis B. Liver Transpl. 2000;6:429-433.
72. Marzano A, Salinzzoni M, Debernardi-Venon W, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol. 2001;34:903-910. (Pubitemid 32595191)
73. Seehofer D, Rayes N, Naumann U, et al. Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation. Transplantation. 2001;72:1381-1385. (Pubitemid 33015762)
74. Demetris AJ, Jaffe R, Sheahan DG, et al. Recurrent hepatitis B in liver allograft recipients. Differentiation between viral hepatitis B and rejection. Am J Pathol. 1986;125:161-172. (Pubitemid 17183769)
75. Portmann B, O'Grady J, Williams R. Disease recurrence following orthotopic liver transplantation. Transplant Proc. 1986;18:136-141. (Pubitemid 17186552)
76. Demetris AJ, Todo S, Van Thiel DH, et al. Evolution of hepatitis B virus liver disease after hepatic replacement. Practical and theoretical considerations. Am J Pathol. 1990;137:667-676. (Pubitemid 20280996)
77. Hart J, Busuttil RW, Lewin KJ. Disease recurrence following liver transplantation. Am J Surg Pathol. 1990;14:79-91. (Pubitemid 20077637)
78. O'Grady JG, Smith HM, Davies SE, et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol. 1992;14:104-111.
79. Davies SE, Portmann BC, O'Grady JG, et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology. 1991;13:150-157.
80. Mason AL, Wick M, White HM, et al. Increased hepatocyte expression of hepatitis B virus transcription in patients with features of fibrosing cholestatic hepatitis. Gastroenterology. 1993;105:237-244. (Pubitemid 23234042)
81. Fung JJ, Eghtesad B, Todo S, et al. Hepatitis B virus (HBV) re-infection following liver transplantation: theory and practice. Clin Transplant. 1995;9:262-268.
82. Wachs ME, Amend WJ, Ascher NL, et al. The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation. 1995;59:230-234.
83. Phillips MJ, Cameron R, Flowers MA, et al. Post-transplant recurrent hepatitis B viral liver disease. Viral-burden, steatoviral, and fibroviral hepatitis B. Am J Pathol. 1992;140:1295-1308.
84. Benner KG, Lee RG, Keeffe EB, et al. Fibrosing cytolytic liver failure secondary to recurrent hepatitis B after liver transplantation. Gastroenterology. 1992;103:1307-1312.
85. Ascher NL, Lake JR, Emond J, et al. Liver transplantation for hepatitis C virus-related cirrhosis. Hepatology. 1994;20:24S-27S. (Pubitemid 24193950)
86. Arnold JC, Tox U, Goeser T, et al. Recurrent hepatitis C virus infection after liver transplantation: long-term follow-up with respect to the HCV genotypes/subtypes. Z Gastroenterol. 1997;35:255-261. (Pubitemid 27217432)
87. Cavallari A, De Raffele E, Bellusci R, et al. De novo hepatitis B and C viral infection after liver transplantation. World J Surg. 1997;21:78-84. (Pubitemid 27026721)
88. Marzano A, Smedile A, Abate M, et al. Hepatitis type C after orthotopic liver transplantation: reinfection and disease recurrence. J Hepatol. 1994;21:961-965.
89. Feray C, Samuel D, Thiers V, et al. Reinfection of liver graft by hepatitis C virus after liver transplantation. J Clin Invest. 1992;89:1361-1365.
90. Weinstein JS, Poterucha JJ, Zein N, et al. Epidemiology and natural history of hepatitis C infections in liver transplant recipients. J Hepatol. 1995;22 (1 suppl):154-159.
91. Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl. 2003;9:S28-S34. (Pubitemid 37408000)
92. Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002;122:889-896. (Pubitemid 34267271)
93. Shuhart MC, Bronner MP, Gretch DR, et al. Histological and clinical outcome after liver transplantation for hepatitis C. Hepatology. 1997;26:1646-1652. (Pubitemid 27520036)
94. Berenguer M, Prieto M, Cordoba J, et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. J Hepatol. 1998;28:756-763. (Pubitemid 28223478)
95. Wali M, Harrison RF, Gow PJ, et al. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut. 2002;51:248-252. (Pubitemid 34791456)
96. Ferrell LD, Wright TL, Roberts J, et al. Hepatitis C viral infection in liver transplant recipients. Hepatology. 1992;16:865-876.
97. Greenson JK, Svoboda-Newman SM, Merion RM, et al. Histologic progression of recurrent hepatitis C in liver transplant allografts. Am J Surg Pathol. 1996;20:731-738. (Pubitemid 26147471)
98. Paya C, Razonable RR. Cytomegalovirus infection after solid organ transplantation. In: Bowden R, Ljungman P, Paya C, eds. Transplant Infections. Vol 1. Philadelphia, PA: Lippincott, Williams and Wilkins; 2003:298-325.
99. Stratta RJ, Shaeffer MS, Markin RS, et al. Cytomegalovirus infection and disease after liver transplantation. An overview. Dig Dis Sci. 1992;37:673-1588
100. Rakela J, Wiesner RH, Taswell HF, et al. Incidence of cytomegalovirus infection and its relationship to donor-recipient serologic status in liver transplantation. Transplant Proc. 1987;19:2399-2402.
101. Arthurs SK, Eid AJ, Pedersen RA, et al. Delayed-onset primary cytomegalovirus disease after liver transplantation. Liver Transpl. 2007;13:1703-1709.
102. Gorensek MJ, Carey WD, Vogt D, et al. A multivariate analysis of risk factors for cytomegalovirus infection in liver transplant recipients. Gastroenterology. 1990;98:1326-1332. (Pubitemid 20143121)
103. Paya CV, Wiesner RH, Hermans PE, et al. Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation: a prospective multivariate time-dependent analysis. J Hepatol. 1993;18:185-195.
104. Holmes RD, Sokol RJ. Epstein-Barr virus and post-transplant lymphoproliferative disease. Pediatr Transplant. 2002;6:456-464. (Pubitemid 35470542)
105. Smets F, Bodeus M, Goubau P, et al. Characteristics of Epstein-Barr virus primary infection in pediatric liver transplant recipients. J Hepatol. 2000;32:100-104. (Pubitemid 30039453)
106. Paya CV, Fung JJ, Nalesnik MA, et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. Transplantation. 1999;68:1517-1525.
107. Randhawa P, Blakolmer K, Kashyap R, et al. Allograft liver biopsy in patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disease. Am J Surg Pathol. 2001;25:324-330. (Pubitemid 32174201)
108. Harris NL, Swerdlow SH, Frizzera G, et al. Post-transplant lymphoproliferative disorders. In: Jaffe ES, Harris NL, Stein H, et al, eds. Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissue. Lyon, France: IARC Press; 2001:264-269. World Health Organization Classification of Tumors.
109. Tsao L, His ED. The clinicopathologic spectrum of post-transplantation lymphoproliferative disorders. Arch Pathol Lab Med. 2007;131:1209-1218.
110. Czaja AJ. Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance. Liver Transpl. 2002;8:505-513. (Pubitemid 34619081)
111. Ayata G, Gordan FD, Lewis WD, et al. Liver transplantation for autoimmune hepatitis: a long-term pathologic study. Hepatology. 2000;32:185-192. (Pubitemid 30614649)
112. Kerkar N, Hadzic N, Davies ET, et al. De-novo autoimmune hepatitis after liver transplantation. Lancet. 1998;351:409-413. (Pubitemid 28064165)
113. Molmenti EP, Netto GJ, Murray NG, et al. Incidence and recurrence of autoimmune/alloimmune hepatitis in liver transplant recipients. Liver Transpl. 2002;8:519-526. (Pubitemid 34619083)
114. Hernandez HM, Kovarik P, Whitington PF, et al. Autoimmune hepatitis as a late complication of liver transplantation. J Ped Gastroenterol Nutr. 2001;32:131-136. (Pubitemid 32280624)
115. Jones DE, James OF, Portman B, et al. Development of autoimmune hepatitis following liver transplantation for primary biliary cirrhosis. Hepatology. 1999;30:53-57. (Pubitemid 29300568)
116. Hubscher SG. Recurrent autoimmune hepatitis after liver transplantation: diagnostic criteria, risk factors and outcome. Liver Transpl. 2001;7:285-291.
117. Snover DC, Sibley RK, Freese DK, et al. Orthotopic liver transplantation: a pathological study of 63 serial liver biopsies from 17 patients with special reference to the diagnostic features and natural history of rejection. Hepatology. 1984;4:1212-1222.
118. Neuberger J. Chronic allograft dysfunction: diagnosis and management. Is it always progressive? Liver Transpl. 2005;11:S63-S68.
119. Evans HM, Kelly DA, McKiernan PJ, et al. Progressive histological damage in liver allografts following pediatric liver transplantation. Hepatology. 2006;43:1109-1117. (Pubitemid 43724635)
120. Berenguer M, Rayon JM, Prieto M, et al. Are post-transplantation protocol liver biopsies useful in the long term? Liver Transpl. 2001;7:790-796.
121. Nakhleh RE, Schwarzenberg SJ, Bloomer J, et al. The pathology of liver allografts surviving longer than one year. Hepatology. 1990;11:465-470. (Pubitemid 20120001)
122. Syn WK, Nightingale P, Gunson B, et al. Natural history of unexplained chronic hepatitis after liver transplantation. Liver Transpl. 2007;13:984-989. (Pubitemid 47163190)
123. Seyam M, Neuberger JM, Gunson BK, et al. Cirrhosis after orthotopic liver transplantation in the absence of primary disease recurrence. Liver Transpl. 2007;13:966-974. (Pubitemid 47163188)
124. Shaikh OS, Demetris AJ. Idiopathic posttransplantation hepatitis? Liver Transpl. 2007;13:943-946.
125. Suciu-Foca N, Ciubotariu R, Liu Z, et al. Persistent allopeptide reactivity and epitope spreading in chronic rejection. Transplant Proc. 1998;30:2136-2137. (Pubitemid 28399453)
126. Rosenthal P, Emond JC, Heyman MB, et al. Pathological changes in yearly protocol liver biopsy specimens from healthy pediatric liver recipients. Liver Transpl Surg. 1997;3:559-562. (Pubitemid 27498466)
127. Riva S, Sonzogni A, Bravi M, et al. Late graft dysfunction and autoantibodies after liver transplantation in children: preliminary results of an Italian experience. Liver Transpl. 2006;12:573-577.
128. Kemnitz J, Gubernatis G, Bunzendahl H, et al. Criteria for the histopathological classification of liver allograft rejection and their clinical relevance. Transplant Proc. 1989;21:2208-2210. (Pubitemid 19131190)
129. Olyaei A, de Mattas AM, Bennett WM. Commonly used drugs and drug interactions. In: Norman DJ, Turka LA, eds. Primer on Transplantation. Mt Laurel, NJ: American Society of Transplantation; 2001:99-113.
130. Wiesner RH, Narayana Menon KV. Late hepatic allograft dysfunction. Liver Transpl. 2001;7 (suppl 1):S60-S73.
131. Lee WM. Drug-induced hepatotoxicity. N Engl J Med. 2003;349:474-485.
132. Yu YY, Ji J, Zhou GW, et al. Liver biopsy in evaluation of complications following liver transplantation. World J Gastroenterol. 2004;10:1678-1681. (Pubitemid 38786957)
133. Demetris AJ, Murase N, Lee RG, et al. Chronic rejection. A general overview of histopathology and pathophysiology with emphasis on liver, heart and intestinal allografts. Ann Transplant. 1997;2:27-44.
134. Freese DK, Snover DC, Sharp HL, et al. Chronic rejection after liver transplantation: a study of clinical, histopathological and immunological features. Hepatology. 1991;13:882-891.
135. Wiesner RH, Ludwig J, Van Hoek B, et al. Chronic hepatic allograft rejection: a review of ductopenic rejection and the vanishing bile duct syndrome. In: Paul LC, Solez K, eds. Organ Transplantation: Long-transplanterm Results. New York, NY: Marcel Dekker; 1992:197-216.
136. Lowes JR, Hubscher SG, Neuberger JM. Chronic rejection of the liver allograft. Gastroenterol Clin North Am. 1993;22:401-420.
137. Candinas D, Gunson BK, Nightingale P, et al. Sex mismatch as a risk factor for chronic rejection of liver allografts. Lancet. 1995;346:1117-1121.
138. Farges O, Nocci Kalil A, Sebagh M, et al. Low incidence of chronic rejection in patients experiencing histological acute rejection without simultaneous impairment in liver function tests. Transplant Proc. 1995;27:1142-1143.
139. Hayashi M, Keeffe EB, Krams SM, et al. Allograft rejection after liver transplantation for autoimmune liver diseases. Liver Transpl Surg. 1998;4:208-214. (Pubitemid 28225647)
140. Wiesner RH, Ludwig J, van Hoek B, et al. Current concepts in cell-mediated hepatic allograft rejection leading to ductopenia and liver failure. Hepatology. 1991;14:721-729.
141. Group EFMLS. Randomized trial comparing tacrolimus (FK506) and cyclosporine in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group. Lancet. 1994;344:423-428.
142. Devlin JJ, O'Grady JG, Tan KC, et al. Ethnic variations in patient and graft survival after liver transplantation. Identification of a new risk factor for chronic allograft rejection. Transplantation. 1993;56:1381-1384.
143. Hubscher SG, Buckels JA, Elias E, et al. Vanishing bile-duct syndrome following liver transplantation: is it reversible? Transplantation. 1991;51:1004-1010.
144. Vierling JM, Fennell RH Jr. Histopathology of early and late human hepatic allograft rejection: evidence of progressive destruction of interlobular bile ducts. Hepatology. 1985;5:1076-1082.
145. Oguma S, Belle S, Starzl TE, et al. A histometric analysis of chronically rejected human liver allografts: insights into the mechanisms of bile duct loss: direct immunologic and ischemic factors. Hepatology. 1989;9:204-209. (Pubitemid 19063302)
146. Wight DA. Chronic liver transplant rejection: definition and diagnosis. Transplant Proc. 1996;28:465-467. (Pubitemid 26073823)
147. White RM, Zajko AB, Demetris AJ, et al. Liver transplant rejection: angiographic findings in 35 patients. Am J Roentgenol. 1987;148:1095-1098. (Pubitemid 17083064)
148. Devlin J, Page AC, O'Grady J, et al. Angiographically determined arteriopathy in liver graft dysfunction and survival. J Hepatol. 1993;18:68-73. (Pubitemid 23166353)
149. Demetris AJ, Fung JJ, Todo S, et al. FK 506 used as rescue therapy for human liver allograft recipients. Transplant Proc. 1991;23:3005-3006.
150. Demetris AJ, Fung JJ, Todo S, et al. Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy: a clinicopathologic study of 96 patients. Transplantation. 1992;53:1056-1062.
151. Herzog D, Soglio DB, Fournet J, et al. Interface hepatitis is associated with a high incidence of late graft fibrosis in a group of tightly monitored pediatric orthotopic liver transplantation patients. Liver Transpl. 2008;14:946-955. (Pubitemid 352003893)
152. Martin S, Russo P, Bubois J, et al. Centrilobular fibrosis in long-term follow-up of pediatric liver transplant recipients. Transplantation. 2002;74:828-836.
153. Quaglia AF, Del Vecchio BG, Greaves R, et al. Development of ductopenic liver allograft rejection include a "hepatitic" phase prior to duct loss. J Hepatol. 2000;33:773-780.
154. Demetris A, Adams D, Bellamy C, et al. Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for histologic staging and reporting of chronic rejection. An International Panel. Hepatology. 2000;31:792-799.
155. Blakolmer K, Seaberg EC, Batts K, et al. Analysis of the reversibility of chronic liver allograft rejection implications for a staging schema. Am J Surg Pathol. 1999;23:1328-1339. (Pubitemid 29517326)
156. Oguma S, Zerbe T, Banner B, et al. Chronic liver allograft rejection and obliterative arteriopathy: possible pathogenic mechanisms. Transplant Proc. 1989;21:2203-2207. (Pubitemid 19131189)
157. Nakanuma Y, Ohta G. Histometric and serial section observations of the intrahepatic bile ducts in primary biliary cirrhosis. Gastroenterology. 1979;76:1326-1332. (Pubitemid 9183089)
158. Crawford AR, Lin XZ, Crawford JM. The normal adult human liver biopsy: a quantitative reference standard. Hepatology. 1998;28:323-331.
159. Matsumoto Y, McCaughan GW, Painter DM, et al. Evidence that portal tract microvascular destruction precedes bile duct loss in human liver allograft rejection. Transplantation. 1993;56:69-75. (Pubitemid 23220574)
160. Harrison RF, Patsiaoura K, Hubscher SG. Cytokeratin immunostaining for detection of biliary epithelium: its use in counting bile ducts in cases of liver allograft rejection. J Clin Pathol. 1994;47:303-308. (Pubitemid 24171695)
161. Demetris AJ, Seaberg EC, Batts KP, et al. Chronic liver allograft rejection: a National Institute of Diabetes and Digestive and Kidney Diseases interinstitutional study analyzing the reliability of current criteria and proposal of an expanded definition. National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Am J Surg Pathol. 1998;22:28-39.
162. Hashimoto E, Shimada M, Noguchi S, et al. Disease recurrence after living liver transplantation for primary biliary cirrhosis: a clinical and histological follow-up study. Liver Transpl. 2001;7:588-595. (Pubitemid 32677882)
163. Dmitrewski JD, Hubsher S, Mayer AD, et al. Recurrence of primary biliary cirrhosis in the liver allograft: the effect of immunosuppression. J Hepatol. 1996;24:253-257. (Pubitemid 26104879)
164. Dubel L, Gorges O, Bismuth H, et al. Kinetics of anti-M2 antibodies after liver transplantation for PBC. J Hepatol. 1995;23:674-681.
165. Sylvestre PB, Batts KP, Burgart LJ, et al. Recurrence of primary biliary cirrhosis after liver transplantation: histologic estimate of incidence and natural history. Liver Transpl. 2003;9:1086-1093. (Pubitemid 37304465)
166. Hubscher S, Elias E, Buckels J, et al. Primary biliary cirrhosis: histological evidence of disease recurrence after liver transplantation. J Hepatol. 1993;18:173-184. (Pubitemid 23246944)
167. Gow PJ, Chapman RW. Liver transplantation for primary sclerosing cholangitis. Liver. 2000;20:97-103. (Pubitemid 30219134)
168. Kugelmas M, Spiegelman P, Osgood MJ, et al. Different immunosuppressive regimens and recurrence of primary scleroisng cholangitis after liver transplantation. Liver Transpl. 2003;9:727-732. (Pubitemid 36874461)
169. Khettry U, Keaveny A, Goldar-Najafi A, et al. Liver transplantation for primary sclerosing cholangitis: a long-term clinicopathologic study. Hum Pathol. 2003;34:1127-1136. (Pubitemid 37466998)
170. Vera A, Moledina S, Gunson B, et al. Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Lancet. 2002;360:1943-1944. (Pubitemid 35472138)
171. Giaziadei IW. Recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl. 2002;8:575-581. (Pubitemid 34752702)
172. Graziadi IW, Wiesner RH, Marotta PJ, et al. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology. 1999;30:1121-1127. (Pubitemid 29510847)
173. Graziadi IW, Wiesner RH, Batts KP, et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology. 1999;29:1050-1056. (Pubitemid 29168735)
174. Gopal DV, Corless CL, Rabkin JM, et al. Graft failure from severe recurrent primary scleroisng cholangitis following orthotopic liver transplantation. J Clin Gastroenterol. 2003;37:344-347.
175. Sebagh M, Yilmaz F, Karam V, et al. The histologic pattern of "biliary tract pathology" is accurate for the diagnosis of biliary complications. Am J Surg Pathol. 2005;29:318-323.
176. Demetris AJ. Distinguishing between recurrent primary sclerosing cholangitis and chronic rejection. Liver Transpl. 2006;12:S68-S72. (Pubitemid 44742529)
177. Rull R, Garcia Valdecasas JC, Grande L, et al. Intrahepatic biliary lesions after orthotopic liver transplantation. Transpl Int. 2001;14:129-134. (Pubitemid 32666975)
178. Huang XQ, Huang ZQ, Duan WD, et al. Severe biliary complications after hepatic artery embolization. World J Gastroenterol. 2002;8:119-123. (Pubitemid 34149773)
179. Lee HW, Suh KS, Shin WY, et al. Classification and prognosis of intrahepatic biliary stricture after liver transplantation. Liver Transpl. 2007;13:1736-1742.
180. Kanel GC, Korula J. Cholestasis and biliary tract disorders. In: Kanel GC, Korula J, eds. Atlas of Liver Pathology. Philadelphia: Elsevier/Saunders; 2005:44-47.
181. Nakazawa Y, Walker NI, Kerlin P, et al. Clinicopathological analysis of liver allograft biopsies with late centrilobular necrosis: a comparative study in 54 patients. Transplantation. 2000;69:1599-1608. (Pubitemid 30845606)
182. Dhillon AP, Burroughs AK, Hudson M, et al. Hepatic venular stenosis after orthotopic liver transplantation. Hepatology. 1994;19:106-111. (Pubitemid 24020479)
183. Sebagh M, Debette M, Sammuel D, et al. "Silent" presentation of veno-occlusive disease after liver transplantation as part of the process of cellular rejection with endothelial predilection. Hepatology. 1999;30:1144-1150.
184. Brunt EM. Liver biopsy interpretation for the gastroenterologist. Curr Gastroenterol Rep. 2000;2:27-32.
185. Lefkowitch JH. Diagnostic issues in liver transplantation pathology. Clin Liver Dis. 2002;6:555-570. (Pubitemid 34755905)
186. Lim J, Keeffe E. Liver transplantation for alcoholic liver disease: current concept and length of sobriety. Liver Transpl. 2004;10:S31-S38. (Pubitemid 39406099)